GRAVITAS-119: Phase I Study of Itacitinib Plus Calcineurin Inhibitors as Prophylaxis for GVHD

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the expanding treatment options for hemophilia A & B

Stacy E. Croteau, MD, MMS
Program Director Guy A. Young, MD
Program Director Released: January 25, 2023

Data on JAK2 V617F molecular response from a study of ruxolitinib in patients with polycythemia vera or essential thrombocythemia, from ASH 2022 and reported by Clinical Care Options (CCO)

New data from APPLY-PNH study of iptacopan in patients with paroxysmal nocturnal hemoglobinuria, presented at ASH 2022 and reported by Clinical Care Options (CCO)

Results from phase II trial of second-in-class oral factor D inhibitor vemircopan in previously untreated patients with PNH, presented at ASH 2022 and reported by Clinical Care Options( CCO)